|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
August 2007FeaturesCover Story Where the Wall Will Fall FirstWould-be makers of follow-on biologics aren’t ready to show their cards, closely guarding their plans for the day the regulatory wall falls. Which classes are likely to be copied first? Pharmacoeconomics Demonstrating the Value of Biologics: A Call to ActionThe author reviews obstacles to the use of economic evaluations for health care payers and strategies to overcome them. Clinical Will Biotechnology Keep the Heart Healthy?Coronary heart disease kills more Americans each year than any
other disease. So why have biotechs lagged in developing treatments? No quick answers, but change is coming. Business Business Savvy in the Age of BiologicsThe uncharted territory of the infusion business is straining
small and large physician practices alike. Unfortunately, there’s no secret passage to staying out of debt. Utilization PA No More?A handful of commercial plans are finding that prior authorization is an ineffective cost control. More efficient options are waiting in the wings. DepartmentsOpeners Nothing Generic About This IssueNothing generic about this issue — the cover story topic or the journal. Editorial CMS Value-Based PurchasingDavid B. Nash, MD, MBA, on the unstoppable trend started by CMS. Washington Watch Budgetary Battles Burden Trial FundingCongress, can you spare a few billion? The NIH could use it for research. Diagnostics and Devices Cheap and Easy Cancer Diagnosis?Better cancer diagnosis, easier — and less costly too. DrugTrack Approvals, FDA Actions, Clinical TrialsFDA approvals and other actions, plus results of key clinical trials. Biotech Business Making a RHIOlistic Effort To Improve Quality of CareThe road to RHIO is not paved with gold, but the destination is priceless. |
|||||